Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Clinical trial NCT05675033 · UNKNOWN

Trial details

NCT number: NCT05675033
Sponsor: Fujian Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Adenocarcinoma Stage IV Non-small Cell Lung Cancer PD-1 Inhibitor VEGF

Start date: 2023-01-10
Primary completion: 2023-01-10
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.